Current therapies for pancreatic ductal adenocarcinoma (PDA) target individual tumor cells.
Focal adhesion kinase (FAK) is activated in PDA, and levels are inversely associated with …

Focal adhesion kinase (FAK) hyperactivation is common in pancreatic ductal
adenocarcinoma (PDAC). A small molecule, GSK2256098 (GlaxoSmithKline), has been …

The non-receptor cytoplasmic tyrosine kinase, Focal Adhesion Kinase (FAK) is known to
play a key role in a variety of normal and cancer cellular functions such as survival …

Focal adhesion kinase (FAK) is a cytoplasmic tyrosine kinase that is overexpressed in many
types of tumors, including pancreatic cancer, and plays an important role in cell adhesion …

Background Interaction with integrin and focal adhesion kinase (FAK) regulates the cancer
cell adhesion and invasion into extracellular matrix (ECM). In addition, phosphorylation of …

Background Pancreatic ductal adenocarcinoma (PDAC) is a very lethal disease, with
minimal therapeutic options. Aberrant tyrosine kinase activity influences tumor growth and is …

Tumor metastasis is a leading cause of cancer-related death. Focal adhesion kinase (FAK)
is a cytoplasmic tyrosine kinase recruited to integrin-mediated matrix attachment sites where …

Pancreatic cancer is a lethal disease accounting for the fourth leading cause of cancer death
in USA. Focal adhesion kinase (FAK) and the insulin-like growth factor-I receptor (IGF-1R) …

Cancer cells are characterized by the ability to grow in an anchorage-independent manner.
The activity of the nonreceptor tyrosine kinase, focal adhesion kinase (FAK), is thought to …

Objective We investigated how pancreatic cancer developed resistance to focal adhesion
kinase (FAK) inhibition over time. Design Pancreatic ductal adenocarcinoma (PDAC) …